ArticleDiabetic medicine : a journal of the British Diabetic Association2016
Recessive mutations in the cancer gene Ataxia Telangiectasia Mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance.
Article in Diabetic medicine : a journal of the British Diabetic Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02733679 (Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Alpha-ketoglutarate mitigates insulin resistance and metabolic inflexibility in a mouse model of Ataxia-Telangiectasia.Nature communications · 2025Article
- Loss of CD98HC phosphorylation by ATM impairs antiporter trafficking and drives glutamate toxicity in Ataxia telangiectasia.Nature communications · 2025Article
- Hepatic fibrosis: a manifestation of the liver disease evolution in patients with Ataxia-telangiectasia.Orphanet journal of rare diseases · 2023Article
- Medicinal Plant Extracts EvaluatedEvidence-based complementary and alternative medicine : eCAM · 2021Review
- The genetic association of the transcription factor NPAT with glycemic response to metformin involves regulation of fuel selection.PloS one · 2021Article
- Ataxia Telangiectasia Mutated Protein Kinase: A Potential Master Puppeteer of Oxidative Stress-Induced Metabolic Recycling.Oxidative medicine and cellular longevity · 2021Review
- Heart failure and diabetes: role of ATM.Current opinion in pharmacology · 2020Review
- Diabetes in Patients With Ataxia Telangiectasia: A National Cohort Study.Frontiers in pediatrics · 2020Article
- DNA Repair Syndromes and Cancer: Insights Into Genetics and Phenotype Patterns.Frontiers in pediatrics · 2020Review
- Diabetes: Is There a Future for Pharmacogenomics Guided Treatment?Clinical pharmacology and therapeutics · 2019Review
- Progressive Liver Disease in Patients With Ataxia Telangiectasia.Frontiers in pediatrics · 2019Article
- Pharmacogenetics of Antidiabetic Drugs.Advances in pharmacology (San Diego, Calif.) · 2018Review
- Is age a risk factor for liver disease and metabolic alterations in ataxia Telangiectasia patients?Orphanet journal of rare diseases · 2017Article
- Review
- Ataxia telangiectasia: a review.Orphanet journal of rare diseases · 2016Review
- Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery.Nature reviews. Endocrinology · 2016Review
- Personalized medicine in diabetes: the role of 'omics' and biomarkers.Diabetic medicine : a journal of the British Diabetic Association · 2016Review
- Recessive mutations in the cancer gene Ataxia Telangiectasia Mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance.Diabetic medicine : a journal of the British Diabetic Association · 2016Article
- Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome.Expert opinion on investigational drugsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
aimTo investigate glucose and insulin metabolism in participants with ataxia telangiectasia in the absence of a diagnosis of diabetes.
methodsA standard oral glucose tolerance test was performed in participants with ataxia telangiectasia (n = 10) and in a control cohort (n = 10). Serial glucose and insulin measurements were taken to permit cohort comparisons of glucose-insulin homeostasis and indices of insulin secretion and sensitivity.
resultsDuring the oral glucose tolerance test, the 2-h glucose (6.75 vs 4.93 mmol/l; P = 0.029), insulin concentrations (285.6 vs 148.5 pmol/l; P = 0.043), incremental area under the curve for glucose (314 vs 161 mmol/l/min; P = 0.036) and incremental area under the curve for insulin (37,720 vs 18,080 pmol/l/min; P = 0.03) were higher in participants with ataxia telangiectasia than in the controls. There were no significant differences between groups in fasting glucose, insulin concentrations or insulinogenic index measurement (0.94 vs 0.95; P = 0.95). The Matsuda index, reflecting whole-body insulin sensitivity, was lower in participants with ataxia telangiectasia (5.96 vs 11.03; P = 0.019) than in control subjects.
conclusionsMutations in Ataxia Telangiectasia Mutated (ATM) that cause ataxia telangiectasia are associated with elevated glycaemia and low insulin sensitivity in participants without diabetes. This indicates a role of ATM in glucose and insulin metabolic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.